Experience of real-life use of dalbavancin as an off-label treatment of complicated infectious diseases in a tertiary care hospital experience “2279

HIGHLIGHTS

SUMMARY

    Dalbavancin is a lipoglycopeptide antibiotic whose mechanism of action involves the disruption of cell wall synthesis by binding to the D-alanyl-D-alanine end of the peptidoglycan structure in the forming cell wall, preventing cross-linking (transpeptidation and transglycosylation) of disaccharide subunits, resulting in bacterial cell death. Dalbavancin is usually used off-label, as it has a powerful activity against Grampositive pathogens that cause bone and joint infections (osteomyelitis), bacteraemias and endocarditis, among others, which are infections that require long-term antibiotic therapy and long periods of hospitalization. Its prolonged action allows for . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?